Annette Stemhagen

Dr. Annette Stemhagen is the Vice President of UBC's Epidemiology and Risk Management, where she provides strategic consultative services to pharmaceutical and biotechnology clients in epidemiology, safety surveillance, and risk management. In addition, she assists other UBC groups in developing and implementing creative and innovative study design solutions to meet client needs. Dr. Stemhagen has more than 25 years of public health epidemiological research experience, including 15 years in safety surveillance of pharmaceutical, biotech and vaccine products. She has specific expertise in design, implementation, and analysis of epidemiologic studies, registries, large streamlined safety studies and actual use and observational studies for products in Phase IIIb and post approval. Dr. Stemhagen has designed and evaluated risk assessment studies, including more than 10 regulatory-mandated long term safety studies. She has also developed risk intervention programs, risk management evaluation studies, and Risk MAPS. Dr. Stemhagen is active in the International Society for Pharmacoepidemiology and the Drug Information Association. In 2004, Dr. Stemhagen was appointed as the industry representative to the FDA Drug Safety and Risk Management Advisory Committee.

Dr. Stemhagen received her undergraduate degree from the University of Pennsylvania, and her Masters and Doctoral Degrees from the University of Pittsburgh Graduate School of Public Health in epidemiology. She holds adjunct faculty appointments at the University of Pennsylvania School of Medicine Center for Epidemiology and Biostatistics and the Temple University School of Pharmacy. Dr. Stemhagen is a Fellow of the International Society for Pharmacoepidemiology.


Annette Stemhagen Dr. Annette Stemhagen is the Vice President of UBC's Epidemiology and Risk Management, where she provides strategic consultative services to pharmaceutical and biotechnology clients in epidemiology, safety surveillance, and risk management. In addition, she assists other UBC groups in developing and implementing creative and innovative study design solutions to meet client needs. Dr. Stemhagen has more than 25 years of public health epidemiological research experience, including 15 years in safety surveillance of pharmaceutical, biotech and vaccine products. She has specific expertise in design, implementation, and analysis of epidemiologic studies, registries, large streamlined safety studies and actual use and observational studies for products in Phase IIIb and post approval. Dr. Stemhagen has designed and evaluated risk assessment studies, including more than 10 regulatory-mandated long term safety studies. She has also developed risk intervention programs, risk management evaluation studies, and Risk MAPS. Dr. Stemhagen is active in the International Society for Pharmacoepidemiology and the Drug Information Association. In 2004, Dr. Stemhagen was appointed as the industry representative to the FDA Drug Safety and Risk Management Advisory Committee. Dr. Stemhagen received her undergraduate degree from the University of Pennsylvania, and her Masters and Doctoral Degrees from the University of Pittsburgh Graduate School of Public Health in epidemiology. She holds adjunct faculty appointments at the University of Pennsylvania School of Medicine Center for Epidemiology and Biostatistics and the Temple University School of Pharmacy. Dr. Stemhagen is a Fellow of the International Society for Pharmacoepidemiology.